Nephrogenic syndrome of inappropriate diuresis is a recently-discovered rare disease caused by gain-of-function mutations of the V2 vasopressin receptor gene, AVPR2. To date, mutations of Phe229 and Arg137 have been identified as gain-of-function mutations in V2 vasopressin receptor (V2R). The mutant receptors lead to hyponatremia, which may lead to clinical symptoms in infants. In this study, we present a newly-identified Ile130Asn (I130N) substitution, causing NSIAD in a family. Characterization of the mutation revealed basal constitutive activity of V2R. We have demonstrated that the I130N mutation results in constitutive cAMP generation in HEK293 cells. Basal activity of the mutant receptor could be blocked by the inverse agonist tolvaptan and arginine-vasopressin stimulation enhanced the cAMP production of I130N-V2R. The mutation causes a biased receptor conformation since the basal cAMP generation activity of I130N does not lead to interaction with β-arrestin. The constitutive activity of the mutant receptor causes constitutive dynamindependent and β-arrestin-independent internalization. The inhibition of the basal internalization using dominant-negative dynamin resulted in an increased cell surface expression. In contrast to the constitutive internalization, agonist-induced endocytosis was β-arrestin dependent. Based on our findings, tolvaptan could be used for treatment of hyponatremia, shown in patients with nephrogenic syndrome of inappropriate diuresis who carry the I130N-V2R mutation.